These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6339786)

  • 41. Plasma concentrations and transperitoneal transport of native insulin and C-peptide in patients on continuous ambulatory peritoneal dialysis.
    Wideröe TE; Smeby LC; Myking OL
    Kidney Int; 1984 Jan; 25(1):82-7. PubMed ID: 6374252
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of peritoneal transfer status on fasting blood glucose in non-diabetic nephropathy patients on continuous ambulatory peritoneal dialysis.
    Yu XF; Zhou YF; Feng L; Zhang DL; Liu WH
    Chin Med J (Engl); 2009 Dec; 122(24):2977-80. PubMed ID: 20137485
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Continuous ambulatory peritoneal dialysis treatment and blood glucose control in diabetics with end-stage diabetic nephropathy].
    Li GW; Liu J; Chen L
    Zhonghua Nei Ke Za Zhi; 1989 Jun; 28(6):360-3, 382. PubMed ID: 2684575
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is continuous ambulatory peritoneal dialysis the best dialysis choice for insulin dependent diabetics?
    Rottembourg J; de Groc F; Poignet JL; Legrain M
    Proc Eur Dial Transplant Assoc; 1983; 19():215-20. PubMed ID: 6348737
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Management of blood glucose in diabetic dialysis patients].
    Hori K; Fujimi S
    Nihon Rinsho; 1992 Jan; 50 Suppl():192-6. PubMed ID: 1578677
    [No Abstract]   [Full Text] [Related]  

  • 46. Serum and dialyzate concentrations of intraperitoneal cephalothin in patients undergoing continuous ambulatory peritoneal dialysis.
    Münch R; Steurer J; Lüthy R; Siegenthaler W; Kuhlmann U
    Clin Nephrol; 1983 Jul; 20(1):40-3. PubMed ID: 6883818
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS).
    Marshall J; Jennings P; Scott A; Fluck RJ; McIntyre CW
    Kidney Int; 2003 Oct; 64(4):1480-6. PubMed ID: 12969169
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glucose and Insulin Response to Peritoneal Dialysis Fluid in Diabetic and Nondiabetic Peritoneal Dialysis Patients.
    Oba I; Mori T; Chida M; Kurasawa N; Naganuma E; Sato E; Koizumi K; Sato S; Tsuchikawa M; Ito S
    Adv Perit Dial; 2015; 31():11-6. PubMed ID: 26714381
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparisons of the peritoneal equilibration test and ultrafiltration in patients with and without diabetes mellitus on continuous ambulatory peritoneal dialysis.
    Chou MY; Kao MT; Lai MN; Chung SY
    Am J Nephrol; 2006; 26(1):87-90. PubMed ID: 16543711
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bidirectional peritoneal transport of albumin in continuous ambulatory peritoneal dialysis.
    Joffe P; Henriksen JH
    Nephrol Dial Transplant; 1995; 10(9):1725-32. PubMed ID: 8559496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intraperitoneal insulin in diabetic CAPD patients.
    Mactier RA; Khanna R
    Int J Artif Organs; 1988 Jan; 11(1):9-12. PubMed ID: 3283057
    [No Abstract]   [Full Text] [Related]  

  • 52. Effect of peritonitis on insulin and glucose absorption during peritoneal dialysis in diabetic rats.
    Mactier RA; Moore H; Khanna R; Shah J
    Nephron; 1990; 54(3):240-4. PubMed ID: 2179758
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intraperitoneal versus subcutaneous insulin in patients on nighttime IPD.
    Bargman JM
    Adv Perit Dial; 1994; 10():116-9. PubMed ID: 7999807
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Absorption and biological effect of intraperitoneal insulin administration in patients with terminal renal failure treated by continuous ambulatory peritoneal dialysis (CAPD).
    Peetoom JJ; Willekens FL; Meinders AE
    Neth J Med; 1985; 28(10):435-41. PubMed ID: 3908952
    [No Abstract]   [Full Text] [Related]  

  • 55. The treatment of diabetic end-stage renal disease with peritoneal dialysis.
    Feriani M; Dell'Aquila R; La Greca G
    Nephrol Dial Transplant; 1998; 13 Suppl 8():53-6. PubMed ID: 9870427
    [No Abstract]   [Full Text] [Related]  

  • 56. [Intermittent peritoneal chronic dialysis in diabetic patients: effect of the technique on blood glucose and protein loss during the procedure].
    García Ortiz R; Gómez M; Olea C
    Rev Med Chil; 1989 Dec; 117(12):1367-73. PubMed ID: 2519375
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.
    Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M
    J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chronic ambulatory peritoneal dialysis.
    Harrington JT
    N Engl J Med; 1982 Mar; 306(11):670-1. PubMed ID: 7035948
    [No Abstract]   [Full Text] [Related]  

  • 59. New prescription of peritoneal dialysis: intermittent ambulatory peritoneal dialysis.
    Okada K; Urae J; Takahashi S
    Nephron; 1996; 74(2):459-61. PubMed ID: 8893188
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of peritoneal glucose load on plasma leptin concentration in continuous ambulatory peritoneal dialysis patients.
    Kim MJ; Kim GA; Lee SW; Song JH; Hyun IY
    Yonsei Med J; 2000 Aug; 41(4):485-90. PubMed ID: 10992810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.